The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/bortezomib/rituxima...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Friedberg, Jonathan W., Vose, Julie M., Kelly, Jennifer L., Young, Faith, Bernstein, Steven H., Peterson, Derick, Rich, Lynn, Blumel, Susan, Proia, Nicole K., Liesveld, Jane, Fisher, Richard I., Armitage, James O., Grant, Steven, Leonard, John P.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2011
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3062293/
https://ncbi.nlm.nih.gov/pubmed/21239695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-11-314708
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars